Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients
作者： Ye Chen , She-Gan Gao , Jian-Min Chen , Gong-Ping Wang , Zeng-Fang Wang
DOI: 10.1007/S12013-014-0345-2
关键词: Internal medicine 、 Carcinoembryonic antigen 、 Lymph node 、 Pathological 、 Medicine 、 Metastasis 、 Antigen 、 Gastroenterology 、 Clinical significance 、 Pancreatic cancer 、 Oncology 、 Cryoablation 、 Biophysics 、 Cell biology 、 Biochemistry 、 General Medicine
摘要: This study aimed to compare the changes and determine clinical significance of carbohydrate antigens CA242, CA199, CA125, carcinoembryonic antigen (CEA), tumor-specific growth factor (TSGF) before after cryoablation by Cryocare system. Thirty-one pancreatic cancer patients were selected receive The serum expression levels CEA, TSGF 1 month treatment determined. Meanwhile, level these factors was also determined in 31 healthy volunteers. parameter analyzed with pathological data. group significantly higher than those control both (P < 0.05). dramatically decreased treatment, which statistically different positive rates CEA much 0.05), rate that lower Serum CA242 correlated tumor diameter, staging, differentiation, lymph node, liver metastasis Except gender, CA199 all other parameters CA125 only differentiation Cryoablation system can decrease TSGF, rate. be important index for assessment. are great value assessment prognosis patients.
springer.com
sci-hub.se 参考文章(18)
Bin Bao, Shadan Ali, Aamir Ahmad, Yiwei Li, Sanjeev Banerjee, Dejuan Kong, Amro Aboukameel, Ramzi Mohammad, Eric Van Buren, Asfar S. Azmi, Fazlul H. Sarkar, Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer Stem Cells and Development. ,vol. 23, pp. 1947- 1958 ,(2014) , 10.1089/SCD.2013.0551
Todd M. Bauer, Bassel F. El-Rayes, Xiaobai Li, Nazik Hammad, Philip A. Philip, Anthony F. Shields, Mark M. Zalupski, Tanios Bekaii-Saab, Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: A pooled analysis of 6 prospective trials Cancer. ,vol. 119, pp. 285- 292 ,(2013) , 10.1002/CNCR.27734
Gang Zhou, Lizhi Niu, David Chiu, Lihua He, Kecheng Xu, Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnology Letters. ,vol. 34, pp. 1235- 1241 ,(2012) , 10.1007/S10529-012-0908-5
Sukhwinder Kaur, Michael J. Baine, Sushovan Guha, Nobuo Ochi, Subhankar Chakraborty, Kavita Mallya, Colleen Thomas, Julia Crook, Michael B. Wallace, Timothy A. Woodward, Maneesh Jain, Shailender Singh, Aaron R. Sasson, Verna Skinner, Massimo Raimondo, Surinder K. Batra, Neutrophil Gelatinase-Associated Lipocalin, Macrophage Inhibitory Cytokine 1, and Carbohydrate Antigen 19-9 in Pancreatic Juice Pancreas. ,vol. 42, pp. 494- 501 ,(2013) , 10.1097/MPA.0B013E31826A8597
Tae Yoo, Woo Jin Lee, Sang Myung Woo, Tae Hyun Kim, Sung-Sik Han, Sang-Jae Park, Sung Ho Moon, Kyung Hwan Shin, Sang Soo Kim, Eun Kyung Hong, Dae Yong Kim, Joong-Won Park, Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics. ,vol. 81, ,(2011) , 10.1016/J.IJROBP.2011.02.063
Uwe Pelzer, Andreas Hilbig, Marianne Sinn, Jens Stieler, Marcus Bahra, Bernd Dörken, Hanno Riess, Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Frontiers in Oncology. ,vol. 3, pp. 155- 155 ,(2013) , 10.3389/FONC.2013.00155
Ji-Cong Gui, Wei-Li Yan, Xing-Dang Liu, CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis Clinical and Experimental Medicine. ,vol. 14, pp. 225- 233 ,(2014) , 10.1007/S10238-013-0234-9
Sundeep Singh, Shou-jiang Tang, Jayaprakash Sreenarasimhaiah, Luis F. Lara, Ali Siddiqui, The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Digestive Diseases and Sciences. ,vol. 56, pp. 2491- 2496 ,(2011) , 10.1007/S10620-011-1709-8
Ching-Wei D. Tzeng, Aparna Balachandran, Mediha Ahmad, Jeffrey E. Lee, Sunil Krishnan, Huamin Wang, Christopher H. Crane, Robert A. Wolff, Gauri R. Varadhachary, Peter W.T. Pisters, Thomas A. Aloia, Jean-Nicolas Vauthey, Jason B. Fleming, Matthew H.G. Katz, Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. Hpb. ,vol. 16, pp. 430- 438 ,(2014) , 10.1111/HPB.12154
Zhe Huang, Fang Liu, Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumor Biology. ,vol. 35, pp. 7459- 7465 ,(2014) , 10.1007/S13277-014-1995-9